|
Mon, 03/10/2025 - 06:21 |
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough |
Trevi Therapeutics |
|
Wed, 03/05/2025 - 14:33 |
Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth |
Kamada |
|
Fri, 05/17/2024 - 00:46 |
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer |
Regulus Therapeutics |
|
Mon, 03/04/2024 - 22:31 |
UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases |
UCB |
|
Thu, 12/15/2022 - 07:38 |
CASI Pharmaceuticals Partner Juventas Announces New Drug Application For CNCT19 Accepted By China National Medical Products Administration |
CASI Pharmaceuticals |
|
Mon, 12/12/2022 - 13:25 |
Regulus Therapeutics Announces Resignation of Board Member |
Regulus Therapeutics |
|
Mon, 11/28/2022 - 19:35 |
Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations |
Regulus Therapeutics |
|
Sun, 11/13/2022 - 21:09 |
Emmaus Life Sciences Reports Q3 2022 Financial Results and Provides Business Update |
Emmaus Life Sciences |
|
Wed, 11/02/2022 - 16:56 |
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Regulus Therapeutics |
|
Thu, 10/27/2022 - 10:27 |
Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting |
Trevi Therapeutics |
|
Thu, 10/27/2022 - 09:21 |
Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 |
Regulus Therapeutics |
|
Tue, 10/11/2022 - 13:33 |
Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option |
Elevar Therapeutics |
|
Thu, 09/22/2022 - 00:46 |
Rivus Pharmaceuticals Closes $132 Million Series B Financing to Advance HU6 for the Treatment of Obesity and Cardio-Metabolic Disorders |
VABIO |
|
Mon, 09/19/2022 - 09:28 |
Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis |
Trevi Therapeutics |
|
Wed, 09/07/2022 - 10:37 |
One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress |
Debiopharm Group |
|
Thu, 09/01/2022 - 19:03 |
Regulus Therapeutics to Participate in Upcoming Investor Conferences |
Regulus Therapeutics |
|
Mon, 08/22/2022 - 11:41 |
Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer |
VABIO |
|
Mon, 08/15/2022 - 01:09 |
Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update |
Emmaus Life Sciences |
|
Wed, 06/29/2022 - 02:20 |
Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio in the Treatment of Prurigo Nodularis |
Trevi Therapeutics |
|
Mon, 06/13/2022 - 20:24 |
Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK in Post-Operative Care |
Trevena |
|
Mon, 06/13/2022 - 07:35 |
Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Regulus Therapeutics |
|
Thu, 06/02/2022 - 00:31 |
Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK |
Regulus Therapeutics |
|
Wed, 05/11/2022 - 00:58 |
Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Regulus Therapeutics |
|
Mon, 05/02/2022 - 21:25 |
Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update |
Emmaus Life Sciences |
|
Tue, 04/12/2022 - 20:53 |
OLINVYK data selected as Presidents Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting |
Trevena |
